Table 1 Clinical characteristics of the... | American Society of Hematology

Table 1

Clinical characteristics of the patients

Patient	Sex/age, y	Age at diagnosis, y	Phase and BCR-ABL transcript at diagnosis	Treatment 1		Treatment 2			Treatment discontinuation			BCR-ABL undetectability (blood samples)
Patient	Sex/age, y	Age at diagnosis, y	Phase and BCR-ABL transcript at diagnosis	Treatment	Duration, y	Yes/no	Treatment	Duration, y	Yes/no	Age at discontinuation, y	Off-therapy duration, y	Duration, y
1	F/66.7	43	CP, b3a2	IFN-α	13.3	No			Yes	55.4	11.3	5.1
2	M/71.8	46	CP, b3a2	IFN-α	9.1	No			Yes	55.1	16.7	4.3
3	F/72.3	57.5	CP, b3a2	IFN-α	6.5	No			Yes	64	8.3	5.8
4	F/69.2	58.1	CP, b3a2	IFN-α	4.0	Yes	IM 400	4.6	Yes	66.8	2.3	4.0
5	F/70	61.6	CP, b3a2	IFN-α	1.3	Yes	IM 400	5.0	Yes	68.1	1.9	5.1
6	F/78.5	74	CP, b3a2	IM 400	4 months	Yes	Dasatinib*	4	No			3.2

Patient	Sex/age, y	Age at diagnosis, y	Phase and BCR-ABL transcript at diagnosis	Treatment 1		Treatment 2			Treatment discontinuation			BCR-ABL undetectability (blood samples)
Patient	Sex/age, y	Age at diagnosis, y	Phase and BCR-ABL transcript at diagnosis	Treatment	Duration, y	Yes/no	Treatment	Duration, y	Yes/no	Age at discontinuation, y	Off-therapy duration, y	Duration, y
1	F/66.7	43	CP, b3a2	IFN-α	13.3	No			Yes	55.4	11.3	5.1
2	M/71.8	46	CP, b3a2	IFN-α	9.1	No			Yes	55.1	16.7	4.3
3	F/72.3	57.5	CP, b3a2	IFN-α	6.5	No			Yes	64	8.3	5.8
4	F/69.2	58.1	CP, b3a2	IFN-α	4.0	Yes	IM 400	4.6	Yes	66.8	2.3	4.0
5	F/70	61.6	CP, b3a2	IFN-α	1.3	Yes	IM 400	5.0	Yes	68.1	1.9	5.1
6	F/78.5	74	CP, b3a2	IM 400	4 months	Yes	Dasatinib*	4	No			3.2

CP indicates chronic phase; and IM 400, imatinib 400 mg daily.

Dasatinib 70 mg twice daily and then 100 mg twice daily.